Peptris Technologies: AI-Driven Drug Discovery in 2026

Peptris Technologies: Revolutionizing Drug Discovery with AI in 2026

Introduction

In the rapidly evolving field of biotechnology, Peptris Technologies stands out as a pioneering force in AI-driven drug discovery. Founded in 2019, the company is revolutionizing the way new drugs are discovered and developed, aiming to reduce the time, cost, and complexity of bringing life-changing therapies to patients worldwide.

About Peptris Technologies

Peptris Technologies Private Limited is headquartered in Bangalore, Karnataka, India. The company operates on a B2B business model and employs fewer than 10 people. The core team includes:

1. Narayanan Venkatasubramanian - Co-Founder
2. Shridhar Narayanan - Co-Founder and Chief Scientific Advisor
3. Amit Mahajan - Co-Founder
4. Anand Budni - Co-Founder

Business Model and Funding

Peptris Technologies follows a Fee-For-Service business model, offering its AI-driven drug discovery services to pharmaceutical companies and biotech firms. The company has raised a total of $9.0M in funding, with notable investors including Tenacity Ventures, Indian Angel Network, and Speciale Invest.

AI-Powered Drug Discovery

Peptris leverages a proprietary AI and machine learning platform that combines unsupervised learning, generative AI, and large language model technologies to design, optimize, and prioritize drug candidates. This innovative approach enables the discovery of Novel Chemical Entities (NCEs), repurposing of approved drugs, and rescue of clinically validated molecules by predicting critical molecular properties and reducing the need for extensive wet-lab experimentation.

Partnerships and Collaborations

Operating through a virtual R&D model, Peptris collaborates with contract research organizations (CROs), biotechnology partners, academic institutions, and pharmaceutical companies to validate and advance its preclinical pipeline. The company has successfully built a portfolio of AI-discovered drug candidates, including assets targeting rare diseases and cancer, and has achieved significant milestones through strategic licensing partnerships and regulatory recognition.

Future Prospects

Looking ahead, Peptris aims to continue its mission of transforming the drug discovery process by delivering innovative, scalable, and data-driven solutions. With expertise spanning computational biology, medicinal chemistry, data science, and artificial intelligence, the company is well-positioned to drive significant advancements in the field of biotechnology.

Frequently Asked Questions

Where is Peptris headquartered?

Peptris is headquartered in Bangalore, Karnataka, India.

What is the business model of Peptris?

Peptris operates on a B2B business model, offering AI-driven drug discovery services.

What is the founding date of Peptris?

Peptris was founded in 2019.

How much funding has Peptris raised till date?

Peptris has raised a total of $9.0M in funding.

Conclusion

Peptris Technologies is making significant strides in the field of AI-driven drug discovery, aiming to revolutionize the way new drugs are developed. With its innovative approach and strategic partnerships, Peptris is poised to deliver transformative solutions that will improve outcomes for patients worldwide.

Call-to-Action

For more startup stories and insights, visit blogy.in.